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Nigeria is Africa’s most 
populous nation, with a 
population of approximately 
140 million people.  Modern 
contraceptive services are 
underutilized in Nigeria which 
has a modern contraceptive 
prevalence rate (CPR) of 11 
percent. The country’s low 
CPR highlights the need for 
innovative programs to increase 
women’s access to contraceptive 
services.
In Nigeria, the majority of contraceptive services are offered in private 
settings, including Patent Medicine (PM) shops. PM shops are infor-
mal businesses owned by Patent Medicine Vendors (PMVs) licensed 
to sell patent or propriety drugs. PMVs sell a range of contraceptive 
commodities including male and female condoms, emergency contra-
ceptives, pills, and intrauterine devices.
Injectable contraception is the most popular modern method in 
Nigeria, accounting for 30 percent of current modern contraceptive 
users. Current regulations do not permit PMVs to sell or administer 
injectable contraceptives because PMVs do not currently receive 
formal training. Instead, they can only refer clients to health facilities 
for injection sale and administration. Nevertheless, some PMVs are 
selling and administering injectable methods in response to high 
demand for them.
Given this situation, now is an opportune time to generate evidence 
that can drive policy action to formally train and engage PMVs in the 
provision of safe injectable contraceptive services as a key strategy in 
increasing women’s access to contraceptive methods.
STUDY OBJECTIVES
The Evidence Project, in collaboration with the Federal Ministry of 
Health (FMOH), is conducting implementation research to:
1. Demonstrate the feasibility of PMVs administering all available 
forms of injectable contraception, including Depo Provera (DMPA) 
and Sayana® Press.
2. Understand women’s experiences using DMPA or Sayana® Press, 
including the quality of care they receive when accessing inject-
able contraceptive services from PMVs.
The FMOH also asked the Evidence Project to develop and coordinate 
training of PMVs so that they have the necessary skills and infor-
mation to sell, counsel, and refer for all contraceptive methods, as 
well as administer all injectable contraceptives, including DMPA and 
Sayana® Press.
The study is taking place in two states: Oyo in the southwest and 
Nassarawa in north central Nigeria. In each state, four Local Govern-
ment Areas (LGAs) will be selected as the study sites (two urban and 
two rural) for a total of eight LGAs.
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THE PILOT INTERVENTION
PMVs who volunteer to participate in the study will take 
part in a five-day, participatory training on providing infor-
mation and counseling to clients on all family planning 
methods and on administering injectable contraceptives. 
The training will cover the differences between intramus-
cular and subcutaneous injectable contraceptives (see 
Box); their safe storage and administration; and counseling 
women on side effects, when to return for the follow-up 
injection, and what to do if an adverse event occurs. 
The research team will establish or strengthen relation-
ships with a number of stakeholders, including the National 
Association of Patent and Proprietary Medicine Dealers 
(NAPMED) whose members will help recruit PMVs for the 
study, review training materials and participate in the 
training, and interpret the study’s findings. The team will 
also work with local government health facilities in the eight 
LGAs to ensure the acceptance of referrals by PMVs. Addi-
tionally, FMOH and LGA health staff will be involved in the 
planning, implementation, and training of PMVs. To reduce 
the likelihood of stock-outs of DMPA and Sayana® Press, 
Society for Family Health (SFH) and DKT will be actively 
involved in this study. SFH and DKT are the respective orga-
nizations responsible for distributing DMPA and Sayana® 
Press in the private sector in Nigeria.
HOW THE DATA ARE BEING COLLECTED
Pre- and post-PMV training surveys
The PMVs will complete a survey pre- and post-training to 
ascertain changes in knowledge and practices related to 
injectable contraceptives. Additionally, follow-up surveys 
will be administered at three, six, and nine months post 
training to assess the PMV’s practices, knowledge and 
skills over time.
Monthly monitoring/supervision of PMVs
Teams of study investigators and Ministry of Health 
officials will monitor activities of trained PMVs through 
monthly follow-up meetings to identify and resolve 
implementation issues. The monitoring visits will track 
progress, challenges, and successes of implementation 
as well as gather information on clients’ experience of 
adverse events.
Client exit interviews and surveys
To obtain female clients’ perspectives, the researchers 
will conduct exit interviews at PM shops of trained PMVs. 
They will also recruit and follow over time a cohort of 
DMPA and Sayana® Press users receiving services from 
trained PMVs, enabling the assessment of continuation 
rates of injectable contraceptive methods.
FOSTERING RESEARCH UTILIZATION
The research team will engage key decision makers, such 
as the FMOH and state and LGA health officials, from the 
beginning of the study; utilize technical working groups to 
discuss emerging findings and lessons; and identify cham-
pions to promote the study findings to key stakeholders, 
such as health officials, NAPMED, PMVs, Pharmacy Council 
of Nigeria, donors, NGOs, etc. A national dissemination 
meeting will be held in Abuja with the key stakeholders to 
review and interpret the results and identify how they can 
be translated into policy. State level meetings also will be 
held to share implementation successes and challenges to 
PMV delivery of injectable contraceptive services.
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Injectable Contraceptive Methods
There are two types of injectable hormonal contracep-
tives: those that are injected intramuscularly, like DMPA, 
and those that are injected subcutaneously, like Sayana® 
Press. In Nigeria, intramuscular injections were the only 
available option for women wishing to use injectable con-
traception until 2014 when Sayana® Press was introduced 
as a second safe and efficacious option. Sayana® Press 
comes as a single dose in a prefilled, sterile syringe, and 
is administered once every three months. It is packaged in 
the Uniject injection system with an autodisposable device 
that eliminates the need to prepare a needle and syringe. 
Because the type of injection is subcutaneous, the needle 
is smaller and thus less painful.
